The Impact of the COVID-19 Pandemic on the Resistance Level of Mycobacterium Tuberculosis in Suspected Tuberculosis Patients at the Surakarta Central General Hospital
Abstract
Background: Analysis of the impact of the Covid-19 pandemic on the resistance level of Mycobacterium tuberculosis (MTb) isolates to Anti Tuberculosis Drugs (ATD) needs to be carried out considering the level of MTB resistance is an important factor in the occurrence of Multidrug-Resistant TB (MDR-TB) in Indonesia. The purpose of the study was to analyze the impact of the Covid-19 pandemic on the level of resistance of MTb isolates of patients with suspected TB in Surakarta.
Subjects and Method: This research is a quantitative descriptive study with a retrospective Cohort based on the medical record data of suspected TB patients at Surakarta Central General Hospital in 2020 – 2021. The sampling technique was random sampling with a total of 200 samples each year. Data analysis used the SPSS 21 program.
Results: Characteristics of respondents with suspected TB patients who visited the Surakarta Central General Hospital in 2020 and 2021, mostly in men and occurring in productive ages 36-55 years. The most effective type of ATD against MTb isolates is Rifampicin with a mean rank of 6.00 and a p=0.035. While Ethambutol is ineffective as an ATD with a mean rank of 58.00 and a p<0.001. The results of the Wilcoxon test analysis showed there was a significant difference in the level of resistance or sensitivity of MTb isolates in 2020 and 2021 with a p-value=0.000.
Conclusion: There is a significant effect of the impact of the Covid-19 pandemic on the level of resistance or sensitivity of MTb isolates of patients with suspected TB in the Surakarta area in 2020 and 2021.
Keywords: pandemic, Covid-19, resistance, MTb isolates, ATD
Correspondence: Yusup Subagio Sutanto. Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sebelas Maret. Jl. Ir. Sutami 36A, Surakarta 57126, Central Java, Indonesia. Email: yusupsubagiosutanto@gmail.com. Mobile: +62811284165.
Indonesian Journal of Medicine (2022), 07(01): 28-38
https://doi.org/10.26911/theijmed.2022.07.01.04
References
Ama PGB, Suhermi, Fradilla F (2020). The influence of clinical factors and regularity of taking medication with the occurrence of MDR TB in the working area of the Pasar Rebo District Health Center. East Jakarta. JIK. 12(1): 1629. https://doi.org/10.37012/jik.v37012i37011.37115.
Farihatun S, Machmud PB (2018). Determinant factors of drop out (DO) among multidrug resistance tuberculosis (MDRTB) patients at Jakarta Province in 2011 to 2015. IJTID. 7(3): 87–92. https://doi.org/10.20473/ijtid.v20477i20473.27793.
Harti AS, Murharyati A, Sulisetyawati SD, Oktariani M (2018). The effectiveness of snail mucus (Achantina fulica) and chitosan towards limfosit proliferation in vitro. Asian J Pharm Clin Res. 11(15): 8588. doi:10.22159/ajpcr.22018.v22111s22153.22130.
Indonesian Ministry of Health (2020). National strategic plan of tuberculosis control 20162020.
Indonesian Ministry of Health (2018). Tuberculosis. Jakarta
Kobayashi N, Hattori T, Akter S, Mizoue T, Ohta K (2017). Treatment outcomes in patients with multidrugresistant tuberculosis in Japan, 20112013. ERJ. 50 (61). https://doi.org/10.1183/1393003.congress1392017.PA1393494
Lan Y, Li Y, Chen L, Zhang J, Zhang H (2019). Drug resistance profiles and trends in drugresistant tuberculosis at a major hospital in Guizhou Province of China. Infect Drug Resist. 12: 211219. doi:210.2147/IDR.S188538.
Li Q, Zhao G, Wu L, Lu M, Liu W, Wu Y (2018). Prevalence and patterns of drug resistance among pulmonary tuberculosis patients in Hangzhou, China. Antimicrob Resist Infect Control. 7(61). doi:10.1186/s13756130181034813757.
Li Y, Cao X, Li S, Wang H, Wei J, Liu P (2016). Characterization of Mycobacterium tuberculosis isolates from Hebei, China: genotypes and drug susceptibility phenotypes. BMC Infect. Dec. 16:107. doi:10.1186/s1287901614412.
Liu Y, Zhang X, Zhang Y, Sun Y, Yao, C, Wang W (2018). Characterization of Mycobacterium tuberculosis strains in Beijing, China: drug susceptibility phenotypes and Beijing genotype family transmission. BMC Infect. 18. doi: 10.1186/s12879120181357812877.
Lu P, Liu Q, Martinez L, Yang H, Lu W, Ding X, Zhu L (2017). Time to sputum culture conversion and treatment outcome of patients with multidrugresistant tuberculosis: a prospective cohort study from urban China. ERJ. 49(3): 14. https://doi.org/10.1183/13993003.1390155813992016.
Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Torrico MM, et al. (2020). MDR/XDRTB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Di. 92S:S15S25. doi:10.1016/j.ijid.2020.1001.1042.
Muhammad M, Fadli F (2019). Analysis of the causative factors of Multi Drug Resistance (MDR) in tuberculosis patients. JPKMI. 6(2): 6267. http://dx.doi.org/10.20527/jpkmi.v20526i20522.27454.
Sun F, Li Y, Chen Y, Guan W, Jiang X, Wang X, Ren F, et al. (2019). Introducing molecular testing of pyrazinamide susceptibility improves multidrugresistant tuberculosis treatment outcomes: a prospective cohort study. ERJ. 53(4): 1801770. DOI: 1801710.1801183/13993003.1390177013992018.
Sutanto YS, Sutanto M, Harti AS (2021). Antituberculosis drugs against the resistance level of Mycobacterium tuberculosis isolates KEMAS. JKM. 17(1): 1423. https:// doi.org/ 10.15294/kemas.v15211i15291.24158.
Sutanto YS, Sutanto M, Harti AS, Puspawati N (2020). The sensitivity test of Mycobacterium tuberculosis isolates from suspect tuberculosis patients to the seromucous of snail and chitosan as an alternative antituberculosis drugs. Asian J Pharm Clin Res. 13(10): 4449. https://doi.org/10.22159/ajpcr.22020. v22113i22110.38266.
Sutanto YS, Sutanto M, Harti AS, Puspawati N (2021a). The potential of snail seromucous and chitosan as bioimmunomodulator for tuberculosis therapy. JSM. 50(11): 31593169. http://doi.org/3110.17576/jsm120211501117501.
Sutanto YS, Sutanto M, Harti AS, Puspawati N (2021b). The sensitivity test of Mycobacterium tuberculosis to snail seromucoid and chitosan in vitro. Biomedika, 14(1), 3646. https://doi.org/10.31001/biomedika.v31014i31001.31128.
Sutanto YS, Sutanto M, Harti AS (2021c). Antituberculosis drugs against the resistance level of Mycobacterium tuberculosis isolates KEMAS JKM. 17 (1): 1423. https:// doi.org/10.15294/kemas.v11i1.24158
Sutanto YS, Sutanto M, Harti, AS, & Puspawati N (2022). The antimicrobial effectiveness of chitosan and polysaccharide of durian peel extract against Mycobacterium tuberculosis isolates. OAMJMS. 9: 326333. https://doi.org/310.3889/oamjms.2022.8088.
Ullah I, Javaid A, Tahir Z, Ullah O, Shah AA, Hasan F, Ayub N (2016). Pattern of drug resistance and risk factors associated with development of drug resistant Mycobacterium tuberculosis in Pakistan. PLoS ONE. 11(1): e0147529. https://doi.org/0147510.0141371/journal.pone.0147529.
World Health Organization (2018). Global Tuberculosis Report 2018. Available online at: https://www.who.int/tb/publications/global_report/en/
Wu X, Yang J, Tan G, Liu H, Liu Y, Guo Y, Gao R, et al. (2019). Drug resistance characteristics of Mycobacterium tuberculosis isolates from patients with tuberculosis to 12 antituberculous drugs in China. Front Cell Infect Microbiol. 9: 345. https://doi.org/310.3389/fcimb.2019.
Yao Z, Zheng Z, Wu K, Zheng J (2020). Immune environment modulation in pneumonia patients caused by Coronavirus: SARSCoV, MERSCoV and SARSCoV2. Aging. 12(9): 76397651.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, et al. (2019). Antibody responses to SARSCoV2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 71(16): 20272034. doi:2010.1093/cid/ciaa2344.
